Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note released on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their price objective on Minerva Neurosciences from $11.00 to $7.00 and set a neutral rating on the stock in a report on Thursday, May 2nd.

Minerva Neurosciences Stock Performance

NERV opened at $3.19 on Thursday. Minerva Neurosciences has a one year low of $2.26 and a one year high of $13.49. The company has a market cap of $22.30 million, a P/E ratio of -0.71 and a beta of 0.13. The business’s 50-day simple moving average is $2.78 and its 200-day simple moving average is $4.60.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.07. As a group, analysts predict that Minerva Neurosciences will post -1.89 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.